PHARMACEUTICAL INDUSTRY BRINGS CANNABIS DRUG TO FDA AFTER DECADES OF U.S. DENYING VALUE OF MARIJUANA
Published on Jan 27, 2018
GW Pharmaceuticals filed with the FDA last year to get the very first marjuana-based medicine approved and circulating the U.S. and now a new study has been published that will continue pushing support in favor of this life-changing medication. The drug called Epidiolex is made of cannabidiol (CBD) and was used in a study treating patients with a rare form of epilepsy. Patients taking the CBD medication experienced a 41% decrease in seizures a month, making this medication hugely successful and hard to ignore. Before the 20th century drug war began cannabis was commonly used to treat patients with epilepys, but ever since it has been a fight using every shred of evidence to bring cannabis back into a positive light. The FDA has until June 27, 2018 to decide to approve Epidiolex or not meaning the medical value for cannabis could be FDA approved very soon.
The medication under investigation is made of cannabidiol, or CBD. In a study published Wednesday in The Lancet, researchers gave either a brand name form of CBD called Epidiolex or a placebo to more than 170 people with Lennox-Gastaut syndrome, a rare, severe and difficult-to-treat form of epilepsy. Adding CBD to other anti-seizure medications cut down on the number of seizures a person experienced each month by 41 percent. By contrast, the placebo reduced the number by about 14 percent.